Yearly Archives: 2025
Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial
Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.
Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor
Owlet’s new release creates the ultimate baby monitoring system for video, sleep, and medical-grade health tracking.
BioUtah Member Appreciation BBQ 2025 Recap
BioUtah Member Appreciation BBQ 2025 Recap
Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump
Kimbell & Associates: Trump Administration Issues MAHA Strategy Report of Recommendations to President Trump
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.
Salt Lake City Angels Invests in Freyya
Salt Lake City Angels Invests in Freyya
Owlet Extends Global Reach with Launch of Medically-Certified Dream Sock™ to South Africa
The wearable baby monitor trusted by millions globally expands reach to three continents, including North America, Europe, and now Africa.
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.
Halia Therapeutics Published in Journey of Drug Targeting
Halia Therapeutics Published in Journey of Drug Targeting
